Pakistan’s pharmaceutical industry is one of the fastest-growing sectors, valued at over PKR 1 trillion as of 2025. With over 700 licensed manufacturers, this sector plays a critical role in national healthcare, exports, and employment. This blog presents detailed insights into the top 10 pharmaceutical companies in Pakistan based on market share, products, innovation, and performance.
Overview of the Pharmaceutical Industry in Pakistan
- Market Size (2025): PKR 1.1 trillion+
- Annual Growth: 21% (2024–2025)
- Top 10 Firms’ Market Share: ~48%
- Major Growth Drivers: Price inflation (69%), volume (3–5%)
- API Import Dependency: 85% of Active Pharmaceutical Ingredients are imported
Read More: Centrum Pfizer Multivitamins in Pakistan – Benefits, Types & Usage Guide 2025
Top 10 Pharmaceutical Companies in Pakistan (2025)
| Rank | Company Name | Founded | Headquarters | Core Strengths | Notable Products / Focus Areas |
|---|---|---|---|---|---|
| 1 | GlaxoSmithKline (GSK) | 1951 | Karachi | Vaccines, OTC, respiratory medicines | Panadol, Augmentin, Sensodyne |
| 2 | Getz Pharma | 1995 | Karachi | Branded generics, international certifications | Cardiovascular, GI, Anti-infectives |
| 3 | Abbott Laboratories | 1948 | Karachi | Pharma, diagnostics, nutrition | Brufen, Ensure, Glucerna |
| 4 | Searle Pakistan | 1965 | Karachi | Biosimilars, nutraceuticals | Cardiovascular, anti-inflammatory |
| 5 | Highnoon Laboratories | 1984 | Lahore | Fast growth, oncology, cardiology | Oncology, Diabetes, Sustainable practices |
| 6 | Ferozsons Laboratories | 1956 | Lahore | Hepatitis C, oncology, gastroenterology | Liver health, Hep C therapies |
| 7 | Martin Dow Group | 1995 | Karachi | Acquisitions, exports, international expansion | Pain, CNS, cardiovascular |
| 8 | Hilton Pharma | 1976 | Karachi | Licensed manufacturing, international alliances | Dermatology, gynecology |
| 9 | Sami Pharmaceuticals | 1971 | Karachi | R&D focused, quality generics | Neurology, GI, diabetes |
| 10 | AGP Limited | 1989 | Karachi | Publicly listed, diversified product base | Infectious disease, dermatology, generics |
Read More: Big Milestone: 90% Medicines Now Locally Produced in Pakistan
Key Industry Trends (2024–2025)
- Exit of MNCs: Companies like Sanofi, Pfizer, Eli Lilly, and Bayer have exited or sold their local operations due to pricing and regulatory challenges.
- API Production Gaps: Pakistan heavily relies on imported raw materials. DRAP is now pushing for local API manufacturing zones.
- Price Deregulation: Non-essential drugs are being deregulated to allow market-based pricing.
- Export Expansion: Export volume reached $235 million in 2023, expected to rise in 2025.
- Digital & Biosimilar Investment: Local firms like Highnoon and Searle are moving into biosimilars and digital health products.
Conclusion
The pharmaceutical sector in Pakistan is evolving rapidly, driven by growing healthcare demand, price adjustments, and local innovation. While multinational exits create gaps, local manufacturers are expanding domestically and internationally. Firms like Getz Pharma, Highnoon, and AGP are strengthening Pakistan’s footprint in regulated and emerging markets. Keep visiting: Bloom Pakistan
